James Appleton, DPM
Foot & Ankle Surgery · Pawtucket, RINPI 1710280037
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,093 of the $9,679 with a category attached, or 73.3%. It is spread thinly across 38 manufacturers, the largest accounting for just 22.7%. Reporting peaked in 2020 at $2,790 and has fallen 77.6% since, to $625 in 2025.
Across 221 payments — averaging $43.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kairos Surgical Inc$2K
- Smith+Nephew$1K
- Zimmer Biomet$1K
- Biotissue Holdings Inc.$680
- Treace Medical Concepts, Inc.$564
- Stryker$478
- plus $3K from 32 others
What the payments were for
- Travel & lodging$4204%
- Food & beverage$7,09373%
- Education$2,16622%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kairos Surgical Inc | 3 | $2,201 |
| Smith+Nephew | 61 | $1,494 |
| Zimmer Biomet | 20 | $1,019 |
| Biotissue Holdings Inc. | 21 | $680 |
| Treace Medical Concepts, Inc. | 4 | $564 |
| Stryker | 5 | $478 |
| Paratek Pharmaceuticals, Inc. | 26 | $469 |
| Integra Lifesciences Corporation | 10 | $463 |
| Amgen | 5 | $227 |
| Kerecis Limited | 3 | $196 |
| International Life Sciences | 1 | $181 |
| Innovation Technologies Inc | 1 | $170 |
| Orthofix Medical, Inc. | 3 | $124 |
| Medtronic(2 entities) | 2 | $119 |
| Vaporox, Inc. | 1 | $118 |
| Melinta Therapeutics, LLC | 1 | $115 |
| Arthrex | 1 | $112 |
| AbbVie | 6 | $107 |
| ANI Pharmaceuticals, Inc. | 6 | $105 |
| Organogenesis Inc. | 5 | $80 |
| Misonix Inc | 5 | $79 |
| Nevro Corp. | 4 | $73 |
| KCI USA, Inc. | 3 | $62 |
| Acell, Inc. | 1 | $60 |
| Bioventus LLC | 3 | $53 |
| Zyla Life Sciences, Inc. | 3 | $49 |
| Lifenet Health | 2 | $45 |
| Sebela Pharmaceuticals Inc. | 3 | $41 |
| Alfasigma USA, Inc. | 2 | $31 |
| IBSA Pharma Inc. | 2 | $30 |
| Hydrofera LLC | 1 | $27 |
| Mimedx Group, Inc. | 1 | $20 |
| Biocomposites Inc | 1 | $19 |
| Reprise Biomedical, Inc. | 1 | $15 |
| Dynasplint Systems Inc. | 1 | $14 |
| Polynovo North America LLC | 1 | $14 |
| DJO, LLC | 1 | $13 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$395
- RAYOS$359
- Lapiplasty System$356
- ORTHOLOC 3DI$232
- Stravix$231
- FLEXBAND$181
- Irrisept$170
- PROstep$143
- PROPHECY$143
- Kerecis Omega3 SurgiClose$132
- Kerecis Omega3 GraftGuide$132
- TMC NANOPLASTY SYSTEM$130
- NEOX$127
- CLARIX$127
- VHT-200 Wound Treatment System$118
- Alps Plates and Instruments$117
- Grafix PRIME$116
- Grafix CORE$116
- Grafix XC$116
- Grafix PL PRIME$116
How this compares
$9,679 in reported general payments places this provider in the 80th percentile of 58 foot & ankle surgery providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 26 | $9,302 |
| Ketoconazole | 89 | $3,117 |
| Ammonium Lactate | 79 | $815 |
| Gabapentin | 57 | $685 |
| Ciclopirox | 20 | $522 |
| Doxycycline Hyclate | 47 | $490 |
| Celecoxib | 12 | $286 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $263 |
| Silver Sulfadiazine | 23 | $217 |
| Terbinafine Hcl | 12 | $141 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $66 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,494 | $9,30226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 58 foot & ankle surgery providers in Rhode Island.
Other foot & ankle surgery in Pawtucket
- Matthew LawrencePawtucket$38K
- Michal SzparaPawtucket$37K
- Aaron ShemenskiPawtucket$7K
- Ashley MastrangeloPawtucket$7K
- Nicole CurreriPawtucket$2K
- Melvin ManciniPawtucket$586
- Christopher DigiovanniProvidence$665K
- Anthony MechrefeWarwick$92K
- Douglas GlodEast Providence$74K
- Michael ReuterBristol$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.